ARS Pharmaceuticals, Inc. SPRY Deferred revenue, net of current portion
Deferred revenue, net of current portion at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s deferred revenue, net of current portion.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s deferred revenue, net of current portion?
- ARS Pharmaceuticals, Inc. (SPRY) reported deferred revenue, net of current portion of $978K in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s deferred revenue, net of current portion changed year-over-year?
- ARS Pharmaceuticals, Inc.'s deferred revenue, net of current portion decreased by 27.0% year-over-year, from $1.34M to $978K.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s deferred revenue, net of current portion?
- Over 4 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s deferred revenue, net of current portion has grown at a -21.6% compound annual growth rate (CAGR), from $3M to $1.13M.